Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70518-3401-05 70518-3401 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 15, 2023 In Use
00069-2522-02 00069-2522 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
00069-4494-02 00069-4494 Elranatamab-bcmm Elrexfio 76.0 mg/1.9mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
71335-2221-08 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
71335-2221-02 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
71335-2221-06 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
71335-2221-03 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
63539-0252-02 63539-0252 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
71335-2221-04 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
71335-2221-07 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
71335-2221-05 71335-2221 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug 15, 2023 In Use
51655-0541-54 51655-0541 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 15, 2023 In Use
70518-3401-06 70518-3401 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 15, 2023 In Use
71288-0409-05 71288-0409 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Aug 14, 2023 In Use
57894-0100-60 57894-0100 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 100.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP17, PARP Oral Aug 11, 2023 In Use
57894-0050-60 57894-0050 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 50.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Oral Aug 11, 2023 In Use
72266-0252-01 72266-0252 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2023 In Use
72266-0253-01 72266-0253 Cisplatin CISPLATIN 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2023 In Use
57894-0470-01 57894-0470 Talquetamab TALVEY 40.0 mg/mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug 9, 2023 In Use
60760-0179-18 60760-0179 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 9, 2023 In Use
57894-0469-01 57894-0469 Talquetamab TALVEY 3.0 mg/1.5mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug 9, 2023 In Use
68462-0896-10 68462-0896 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug 9, 2023 In Use
70518-1585-04 70518-1585 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 9, 2023 In Use
68462-0897-10 68462-0897 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug 9, 2023 In Use
55154-4310-00 55154-4310 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Aug 8, 2023 Nov 30, 2025 In Use

Found 11465 results — Export these results